WHAT THEY ARE SAYING: LOWERING Rx PRICES & HOLDING BIG PHARMA ACCOUNTABLE TOP PRIORITY IN 2020

01-14-2020 Blog Posts

Editorial Boards, Lawmakers and More Reiterate Need for Market-Based Solutions to Out-of-Control Prescription Drug Prices in 2020 Right on cue, Big Pharma kicked off the New Year by raising prices on 2,167 prescription drugs in the first week of 2020.  The new round of price hikes have added to the momentum to pass bipartisan market-based […]

BIG PHARMA WATCH: HEADLINES FROM BIG PHARMA’S 2020 PRICE HIKE BONANZA

01-13-2020 Blog Posts

News from First Weeks of New Year Underscores Urgent Need for Action in Congress In case you missed it, Big Pharma has hiked prices on 2,167 prescription drugs so far this year – proving once again that without legislative action, brand name drug makers will continue to price-gouge American patients. Among the companies hiking prices […]

CSRXP: BIG PHARMA THUMBS ITS NOSE AT STRUGGLING AMERICANS WITH NEW YEAR PRICE HIKES

01-2-2020 Blog Posts

Drug Makers, Including Brand Name Giants Like Pfizer, Increase Prices on More Than 200 Prescription Drugs Despite Mounting Crisis of Affordability For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Thursday in response to a new analysis which found drug makers, including brand […]

Big Pharma’s Price-Gouging and Anti-Competitive Tactics Drive Increased Rx Spending

12-13-2019 Blog Posts

CMS Report Demonstrates Impact of Out-of-Control Launch Prices and Tactics That Prevent Patients From Accessing Affordable Alternatives In case you missed it, according to the Centers for Medicare and Medicaid Services’ (CMS) annual report on health care spending, the pricing practices and anti-competitive tactics of Big Pharma kept drug costs rising last year — even […]

BIG PHARMA WATCH: NEW STUDY FINDS PRICE HIKES DRIVEN BY QUEST FOR HIGHER PROFITS, NOT R&D

12-4-2019 Blog Posts

Analysis of Multiple Sclerosis Drug Pricing Undercuts Drug Makers’ Bogus “Innovation” Rhetoric A new study published in the American Academy of Neurology finds the staggering price of medications to treat multiple sclerosis (MS), a rare neurological disorder, is driven largely by profit motivations – not research and development (R&D). These findings undermine Big Pharma’s bogus […]

ICYMI: Political Courage Needed to Deliver on Drug Prices

11-25-2019 Blog Posts

Political Courage Needed to Deliver on Drug Prices By Lauren Aronson Real Clear Health November 22, 2019 The egregious pricing behavior of pharmaceutical giants has sparked a crisis of prescription drug affordability in America. Now, after months of dedicated attention to this crisis and unprecedented momentum for action in Washington, the pathway to results for […]

ICYMI: GALLUP FINDS NEARLY 58 MILLION AMERICANS UNABLE TO AFFORD THEIR PRESCRIPTION DRUGS, UP FOUR PERCENT FROM JANUARY

11-13-2019 Blog Posts

Nine in Ten Surveyed Adults Believe Rx Prices “Much Higher” Or “Somewhat Higher” Than Reasonable A new Gallup survey demonstrates the rising toll of out-of-control prescription drug prices on American patients and families. According to the survey, nearly 23 percent of Americans, approaching 58 million U.S. adults, say they have been unable to afford drugs […]

SECOND OPINION: BIG PHARMA SQUARELY TO BLAME FOR RISING MEDICARE PREMIUMS

11-12-2019 Blog Posts

Drug Makers Cry ‘False Narrative’ Over Latest Repot Highlighting Toll of the Industry’s Egregious Pricing Practices Last week, the Centers for Medicare & Medicaid Services (CMS) released a new report attributing premium increases for Medicare Part B beneficiaries to rising drug prices. Like clockwork, Big Pharma immediately attempted to evade responsibility by claiming that “the […]

Q3 Earnings: Big Pharma Keeps The Good Times Rolling While Hiking Prices

11-7-2019 Blog Posts

Q3 Earnings: Big Pharma Keeps The Good Times Rolling While Hiking Prices Top Brand Name Drug Makers Best Earnings Forecasts While Evading Accountability And that’s a wrap! Three weeks of earnings calls have proven, yet again, that Big Pharma’s top concern is padding their bottom line and keeping a profit gravy train running – not […]

AMERICANS AGREE: CONGRESS MUST ACT TO HOLD BIG PHARMA ACCOUNTABLE AND LOWER DRUG PRICES

11-4-2019 Blog Posts

Solutions to Reform Medicare Part D, Increase Competition and Boost Transparency Have Broad Bipartisan Support, Should Be Swiftly Passed THE CRISIS OF RISING PRESCRIPTION DRUG PRICES The anti-competitive tactics and price-gouging practices of Big Pharma have created a crisis of prescription drug affordability in America. Today, as many as one-in-four Americans are unable to afford […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.